Analytical Review of Nanoparticles and Nano-Based Systems for Targeted Therapy of Endometrial Cancer: Insights from Cellular, Clinical and Animal Studies
Resumo
Abstract: Background: Endometrial cancer is among the most prevalent gynecological malignancies worldwide. Despite advances in conventional therapeutic approaches, treatment outcomes are often constrained by challenges such as systemic toxicity, therapeutic resistance, and insufficient target specificity. Nanomedicine has emerged as a promising strategy to overcome these limitations by enhancing both diagnostic accuracy and therapeutic efficacy. This review aimed to critically evaluate the current applications of nanoparticles and nano-engineered systems in the diagnosis and treatment of endometrial cancer and endometriosis.
Methods: An analytical review was conducted using literature retrieved from PubMed, Scopus, and Web of Science databases. Relevant studies published between 2010 and 2025 were systematically screened using predefined keywords related to nanotechnology, endometrial cancer, and endometriosis. Eligible publications included in vitro and in vivo preclinical investigations, animal studies, and comprehensive review articles. Data were extracted and synthesized through a qualitative thematic approach to identify major advances and emerging trends in nano-based diagnostic and therapeutic platforms.
Results: The reviewed evidence demonstrated that a wide range of nanoparticle formulations and nano-delivery systems, including NP@AZL, LDE, SPION@miR-326, CNP, FOL–PEG–PLGA loaded with paclitaxel, CXCR4-targeted nanotherapeutics, nMIL-100 (Fe), porphysomes, and tamoxifen-loaded solid lipid nanoparticles (Tamoxifen-SLN), exhibited considerable therapeutic and diagnostic potential. Across cellular, animal, and clinical models, these nanoplatforms effectively suppressed tumor cell proliferation, induced apoptosis, inhibited angiogenesis and metastatic progression, improved lymph node detection, and reduced the adverse effects commonly associated with conventional anticancer therapies.
Conclusion: Nano-based delivery systems and engineered nanoparticles represent a promising avenue for improving the precision and effectiveness of endometrial cancer management. By facilitating targeted drug delivery and enhancing diagnostic performance while minimizing systemic toxicity, these technologies may contribute substantially to the future development of personalized therapeutic strategies for endometrial malignancies.
Palavras-chave
Referências
ALEXIS, F.; et al. New frontiers in nanotechnology for cancer treatment. Urologic Oncology: Seminars and Original Investigations, p. 74-85, 2008.
AMANT, F.; et al. Endometrial cancer. The Lancet, v. 366, n. 9484, p. 491-505, 2005.
BEDIN, A.; et al. Nanotechnology for the treatment of deep endometriosis: uptake of lipid core nanoparticles by LDL receptors in endometriotic foci. Clinics (São Paulo), v. 74, p. e989, 2019.
BRAUN, M. M.; OVERBEEK-WAGER, E. A.; GRUMBO, R. J. Diagnosis and management of endometrial cancer. American Family Physician, v. 93, n. 6, p. 468-474, 2016.
CAI, Y.; et al. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Current Medicinal Chemistry, v. 28, n. 42, p. 8755-8781, 2021.
CROSBIE, E. J.; et al. Endometrial cancer. The Lancet, v. 399, n. 10333, p. 1412-1428, 2022.
DENSCHLAG, D.; ULRICH, U.; EMONS, G. The diagnosis and treatment of endometrial cancer: progress and controversies. Deutsches Ärzteblatt International, v. 108, n. 34-35, p. 571, 2011.
DESCHLAG D, Ulrich U, Emons G. The diagnosis and treatment of endometrial cancer: progress and controversies. Dtsch Arztebl Int. 2011;108(34-35):571.
EBEID, K.; et al. Synthetically lethal nanoparticles for treatment of endometrial cancer. Nature Nanotechnology, v. 13, n. 1, p. 72-81, 2018.
EDWARDS, K.; et al. Hyaluronic acid-functionalized nanomicelles enhance SAHA efficacy in 3D endometrial cancer models. Cancers, v. 13, n. 16, p. 4032, 2021.
GAO, Y.; et al. Superparamagnetic iron oxide nanoparticle-mediated expression of miR-326 inhibits human endometrial carcinoma stem cell growth. International Journal of Nanomedicine, v. 14, p. 2719-2731, 2019.
GMEINER, W. H.; GHOSH, S. Nanotechnology for cancer treatment. Nanotechnology Reviews, v. 3, n. 2, p. 111-122, 2014.
GONG, X.; et al. Enhancing nanocatalyst-driven chemodynamic therapy for endometrial cancer cells through inhibition of PINK1/Parkin-mediated mitophagy. International Journal of Nanomedicine, v. 16, p. 6661-6679, 2021.
GULBAY, G.; SECME, M.; ILHAN, H. Exploring the potential of thymoquinone-stabilized selenium nanoparticles in HEC1B endometrial cancer cells revealing enhanced anticancer efficacy. ACS Omega, v. 8, n. 42, p. 39822-39829, 2023.
GULBAY, G.; SECME, M.; ILHAN, H. Exploring the potential of thymoquinone-stabilized selenium nanoparticles in HEC1B endometrial cancer cells revealing enhanced anticancer efficacy. ACS Omega, v. 8, n. 42, p. 39822-39829, 2023.
HERRERA, F. G.; et al. Long-term outcome and late side effects in endometrial cancer patients treated with surgery and postoperative radiation therapy. Annals of Surgical Oncology, v. 21, n. 7, p. 2390-2397, 2014.
HILL, E. K.; DIZON, D. S. Medical therapy of endometrial cancer: status and promising novel treatments. Drugs, v. 72, n. 5, p. 705-713, 2012.
HORIKOSHI, S.; SERPONE, N. Introduction to nanoparticles. Microwaves in Nanoparticle Synthesis: Fundamentals and Applications, p. 1-24, 2013.
HUANG, T.; et al. Azelnidipine nanoparticles break calcium homeostasis and induce severe ER stress combined with medroxyprogesterone acetate for endometrial cancer therapy. Nano Today, v. 47, p. 101682, 2022.
JAVID, S.; et al. Effects of tamoxifen-loaded solid lipid nanoparticles on the estrogen receptor-α (ER-α) and vascular endothelial growth factor-A (VEGF-A) genes expression in the endometrial tissue of ovariectomized female Sprague-Dawley rats. International Journal of Biological Macromolecules, v. 96, p. 706-712, 2017.
JEDRYKA, M. A.; et al. Superparamagnetic iron oxide nanoparticles as a tracer for sentinel lymph node mapping in endometrial cancer. International Journal of Molecular Sciences, v. 26, n. 2, p. 781, 2025.
LIANG, C.; et al. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. Bioorganic & Medicinal Chemistry, v. 19, n. 13, p. 4057-4066, 2011.
LIANG, S.; et al. Carbon nanoparticles combined with indocyanine green for sentinel lymph node detection in endometrial carcinoma. Journal of Surgical Oncology, v. 124, n. 3, p. 411-419, 2021.
MEDINA-GUTIÉRREZ, E.; et al. Potent anticancer activity of CXCR4-targeted nanostructured toxins in aggressive endometrial cancer models. Cancers, v. 15, n. 1, p. 85, 2022.
MELLO TC. In vitro assessment of the probiotic properties of lactic acid bacteria isolated from Minas artisanal cheese from Campo das Vertentes, Minas Gerais, Brazil. Rev Bras Hig Sanid Anim. 2024. Available from: http://dx.doi.org/10.5935/1981-2965.20240002 http://www.higieneanimal.ufc.br/view
MOHANRAJ, V. J.; CHEN, Y. Nanoparticles-a review. Tropical Journal of Pharmaceutical Research, v. 5, n. 1, p. 561-573, 2006.
MURRAY, A. M.; SWINGLE, K. L.; MITCHELL, M. J. Engineering nanoparticles for gynecologic cancer therapy. ACS Nano, v. 19, n. 34, p. 30758-30785, 2025.
NAGUIB, Y. W.; et al. Ciprofloxacin derivative-loaded nanoparticles synergize with paclitaxel against type II human endometrial cancer. Small, v. 20, n. 41, p. 2302931, 2024.
PAMAM-coated PLGA-PEG nanoparticles. Drug Delivery and Translational Research, v. 12, n. 7, p. 1684-1696, 2022.
PASSARELLO, K.; KURIAN, S.; VILLANUEVA, V. Endometrial cancer: an overview of pathophysiology, management, and care. Seminars in Oncology Nursing, p. 157-165, 2019.
PHILP, L.; et al. Use of porphysomes to detect primary tumour, lymph node metastases, intra-abdominal metastases and as a tool for image-guided lymphadenectomy: proof of concept in endometrial cancer. Theranostics, v. 9, n. 9, p. 2727-2740, 2019.
ROWLANDS, C. E.; et al. Particles and prejudice: nanomedicine approaches to reducing health disparities in endometrial cancer. Small, v. 20, n. 41, p. 2300096, 2024.
STARLING, B. R.; et al. Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients. Cancer Chemotherapy and Pharmacology, v. 83, n. 1, p. 61-70, 2019.
SU, J.; et al. Decorated silver nanoparticles over guar gum-encapsulated Fe3O4 NPs for the catalytic reduction of 4-nitrophenol followed by study of anti-endometrial cancer potential. Journal of Organometallic Chemistry, v. 1015, p. 123225, 2024.
TAO, S.; et al. Characteristics of systematic lymph node dissection and influencing factors of sentinel lymph node biopsy using carbon nanoparticles in endometrial carcinoma: a single-center study. World Journal of Surgical Oncology, v. 21, n. 1, p. 39, 2023.
TOCZEK, J.; et al. Benefit of silver and gold nanoparticles in wound healing process after endometrial cancer protocol. Biomedicines, v. 10, n. 3, p. 679, 2022.
WIWATCHAITA WEE, K.; et al. The MEK 1/2 inhibitor PD98059 exhibits synergistic anti-endometrial cancer activity with paclitaxel in vitro and enhanced tissue distribution in vivo when formulated into.
YANG, L.; et al. Combination of disulfiram and copper-cysteamine nanoparticles induces mitochondria damage and promotes poptosis in endometrial cancer. Bioactive Materials, v. 36, p. 96-111, 2024.
YANG, X.; et al. Targeting cancer etabolism plasticity with JX06 nanoparticles via inhibiting PDK1 combined with metformin for endometrial cancer patients with diabetes. Advanced Science, v. 9, n. 8, p. 2104472, 2022.
ZUO, J.; et al. Comparison study of laparoscopic sentinel lymph node mapping in endometrial carcinoma using carbon nanoparticles and lymphatic pathway verification. Journal of Minimally Invasive Gynecology, v. 26, n. 6, p. 1125-1132, 2019.
This is an open-access article distributed under the terms of the Creative Commons Attribution License
Apontamentos
- Não há apontamentos.
Visitas